Long-term postoperative follow-up results of transobturator autologous rectus fascial sling versus transobturator tension-free vaginal tapes for female stress urinary incontinence: Randomized controlled clinical trial.

AIMS: To evaluate the outcomes of a new surgical technique for the treatment of stress urinary incontinence (SUI). METHODS: This randomized study included 132 index patients from January 2017 to May 2021, 60 applied with autologous facia and 60 with transobturator tension-free vaginal tape (TVT-O). The primary endpoint was dryness (negative stress test and 0 pad use per day) and this was assessed at 3, 6, 12, and 24 months. The secondary endpoints were the International Consultation on Incontinence Questionnaire short form (ICIQ-SF) and the urinary incontinence quality of life (QoL) at 3, 6, 12, and 24 months. RESULTS: The dryness rate at 24 months was 92.4% (49/53) for patients with transobturator autologous rectus fascial sling (TO-AFS) and 94.6% (53/56) for those with TVT-O (p = 0.47). No difference was determined between the TO-AFS and TVT-O groups in respect of the ICIQ-SF and QoL scores at 2 years postoperatively (p = 0.87). There were five postoperative complications in the TO-AFS group (one urinary retention, one hematoma at suprapubic incision line, and three intermittent groin pains) and four in the TVT-O group (four persistent groin pain) (p = 0.98). CONCLUSIONS: The objective cure rates of the 24-month outcomes of TO-AFS indicate that this novel surgical technique seems to be a highly effective, safe, and feasible procedure for the treatment of SUI, but further studies including long-term follow-up are mandatory to confirm these preliminary data.

Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.

OBJECTIVE: The main objective of this study was to evaluate the efficacy of tamsulosin or mirabegron on ureteral stent-related symptoms. PATIENTS AND METHODS: This was a prospective, randomized, controlled, and single-blinded study. In total, 180 patients who had undergone ureterolithotripsy and ureteral stent insertion were included. Patients were randomly divided into three groups as follows: Group 1 was the control group taking placebo; group 2 was administered tamsulosin (0.4 mg) once a day; and group 3 received mirabegron (50 mg) once a day. The Turkish version of the ureteral stent symptom questionnaire was filled out after 4 weeks. RESULTS: After excluding patients who were lost to follow-up, 161 patients were included in the final analysis. Analgesic usage doses were lower in the tamsulosin (5.1 ± 1.8) and mirabegron (4.5 ± 1.4) groups than in the control group (5.9 ± 2.1; P < .001). The urinary symptoms score was lower in tamsulosin group than it was in the control group (22.1 vs 27.8; P = .001); however, the other scores (body pain, general health, work performance, sexual matters, and other problems) were similar between the groups. CONCLUSIONS: Tamsulosin improves only urinary symptoms due to the ureteral stent and decreases the need for analgesics. Mirabegron has no effect on ureteral stent-related symptoms, but it decreases analgesic need.

Using a checklist to increase the effectiveness of behavioral therapy for overactive bladder: A prospective randomized controlled trial.

AIM: To evaluate the benefits of a newly established checklist form of behavioral therapy for overactive bladder (OAB). METHODS: Of a total of 180 patients suffering eight or more micturitions, two or more nocturia, seven or more urgency, or four more urinary urgency incontinence (UUI) episodes per day according to a 3-day bladder diary, 155 were randomly divided into four groups. Group I (n = 29) patients were instructed to apply only behavioral therapy as a written guideline and group II (n = 27) patients were instructed to apply behavioral therapy with a written checklist. Group III (n = 26) patients received medical treatment plus behavioral therapy without a checklist. Group IV (n = 28) patients received medical treatment with a written checklist over a 6-month period. RESULTS: A total of 110 participants completed the study period. The demographic data and baseline voiding parameters such as frequency, urgency, nocturia, and UUI of the participants in all four groups were similar (P > 0.05 for all). At the end of the study period, the highest rates of treatment response (64.3%) and adherence (85.7%) were determined for the patients with antimuscarinic drugs plus checklist. The persistence rate of patients using antimuscarinics with the checklist was higher than that of those using antimuscarinics plus a written guideline of behavioral therapy (75.4% vs 60.2%). CONCLUSION: The effectiveness of behavioral therapy for OAB can be improved with this newly designed checklist. In addition, the adherence and persistence rate of medical treatment may also improve with the checklist used.